Skip to main content
Log in

Should aspirin be continued in patients started on warfarin?

A systematic review and meta-analysis

  • Review
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

BACKGROUND AND OBJECTIVE: Clinicians frequently face the decision of whether to continue aspirin when starting patients on warfarin. We performed a meta-analysis to characterize the tradeoffs involved in this common clinical dilemma.

DATA SOURCES: Multiple computerized databases (1966 to 2003), reference lists of relevant articles, conference proceedings, and queries of primary authors.

STUDY SELECTION: Randomized trials comparing warfarin plus aspirin versus warfarin alone. Studies with target international normalized ratios (INRs) <2 were excluded.

DATA EXTRACTION: Two reviewers independently extracted baseline data and major outcomes: rates of thromboembolism, hemorrhage, and all-cause mortality.

DATA SYNTHESIS: Nine studies met the inclusion criteria. Of the five that enrolled patients with mechanical heart valves, four used the same target INR in both groups, while one used a reduced target INR for the warfarin plus aspirin group. Pooling the results of the first four studies demonstrated that combination of warfarin plus aspirin significantly decreased thromboembolic events (relative risk [RR], 0.33; 95% confidence interval [CI], 0.19 to 0.58), increased major bleeding (RR, 1.58; 95% CI, 1.02 to 2.44), and decreased all-cause mortality (RR, 0.43; 95% CI, 0.23 to 0.81) compared to warfarin alone. The one valve trial using a reduced INR in the warfarin plus aspirin group reported no difference in thromboembolic outcomes but found decreased major bleeding and a significant mortality benefit with combination therapy. Of the remaining trials, three evaluated a warfarin indication not routinely used in the United States (post-myocardial infarction), and the only trial that considered atrial fibrillation was terminated early due to inadequate enrollment.

CONCLUSIONS: For mechanical heart valve patients, the benefits of continuing aspirin when starting warfarin therapy are clear. For other routine warfarin indications, there are not adequate data to guide this common clinical decision.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Steering Committee of the Physicians’ Health Study Research Group final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321:129–35.

    Google Scholar 

  2. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106.

    Google Scholar 

  3. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet. 1992;340:1421–5.

    Article  PubMed  CAS  Google Scholar 

  4. National Center for Health Statistics. Center for Disease Control and Prevention. Available at: http://www.cdc.gov/nchs/. Accessed 2002.

  5. Abdelhafiz AH. A review of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation. Clin Ther. 2001;23:1628–36.

    Article  PubMed  CAS  Google Scholar 

  6. Anonymous. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–57.

  7. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med. 1999;131:688–95.

    PubMed  CAS  Google Scholar 

  8. Cannegieter SC, Rosendaal FR, Wintzen AR. Optimal oral anti-coagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11–7.

    Article  PubMed  CAS  Google Scholar 

  9. Heras M, Chesebro JH, Fuster V, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995;25:1111–9.

    Article  PubMed  CAS  Google Scholar 

  10. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. Circulation. 1996;93:2212–45.

    PubMed  CAS  Google Scholar 

  11. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 1999;100:1016–30.

    PubMed  CAS  Google Scholar 

  12. Dale J, Myhre E, Storstein O, Stormorken H, Efskind L. Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled clinical study in patients with aortic ball valves. Am Heart J. 1977;94:101–11.

    Article  PubMed  CAS  Google Scholar 

  13. Altman R, Boullon F, Rouvier J, Raca R, de la Fuente L, Favaloro RG. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg. 1976;72:127–9.

    PubMed  CAS  Google Scholar 

  14. Review Manager (RevMan). The Cochrane Collaboration. November 4, 2002. Available at: http://www.cochrane-net.org/revman/. Accessed 2002.

  15. Laffort P, Roudaut R, Roques X, et al. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: a clinical and transesophageal echocardiographic study. J Am Coll Cardiol. 2000;35:739–46.

    Article  PubMed  CAS  Google Scholar 

  16. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med. 1993;329:524–9.

    Article  PubMed  CAS  Google Scholar 

  17. Dale J, Myhre E, Loew D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am Heart J. 1980;99:746–52.

    Article  PubMed  CAS  Google Scholar 

  18. Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg. 1997;113:910–6.

    Article  PubMed  CAS  Google Scholar 

  19. Huynh T, Theroux P, Bogaty P, Nasmith J, Solymoss S. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation. 2001;103:3069–74.

    PubMed  CAS  Google Scholar 

  20. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969–74.

    Article  PubMed  CAS  Google Scholar 

  21. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 Research G. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360:109–13.

    Article  PubMed  Google Scholar 

  22. Lechat P, Lardoux H, Mallet A, et al. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; FFAACS). Cerebrovasc Dis. 2001;12:245–52.

    Article  PubMed  CAS  Google Scholar 

  23. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1 suppl):8S-21S.

    Article  PubMed  CAS  Google Scholar 

  24. Anonymous. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84:527–39.

  25. Anonymous. Warfarin versus aspirin for prevention of thromboem-bolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687–91.

  26. Fiore LD, Ezekowitz MD, Brophy MT, et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 2002;105:557–63.

    Article  PubMed  CAS  Google Scholar 

  27. O’Connor CM, Gattis WA, Hellkamp AS, et al. Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). Am J Cardiol. 2001;88:541–6.

    Article  PubMed  CAS  Google Scholar 

  28. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA. 1999;282:2058–67.

    Article  PubMed  CAS  Google Scholar 

  29. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492–501.

    PubMed  CAS  Google Scholar 

  30. Segal JB, McNamara RL, Miller MR, et al. Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med. 2000;15:56–67.

    Article  PubMed  CAS  Google Scholar 

  31. Anonymous. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet. 1998;351:233–41.

  32. Yasaka M, Yamaguchi T. Secondary prevention of stroke in patients with nonvalvular atrial fibrillation: optimal intensity of anticoagulation. CNS Drugs. 2001;15:623–31.

    Article  PubMed  CAS  Google Scholar 

  33. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441–8.

    Article  PubMed  Google Scholar 

  34. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis. 1999;9:215–7.

    Article  PubMed  CAS  Google Scholar 

  35. Loewen P, Sunderji R, Gin K. The efficacy and safety of combination warfarin and ASA therapy: a systematic review of the literature and update of guidelines. Can J Cardiol. 1998;14:717–26.

    PubMed  CAS  Google Scholar 

  36. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89:635–41.

    PubMed  CAS  Google Scholar 

  37. Cappelleri JC, Fiore LD, Brophy MT, Deykin D, Lau J. Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: a meta-analysis. An Heart J. 1995;130:547–52.

    Article  CAS  Google Scholar 

  38. Altman R, Rouvier J, Gurfinkel E. Oral anticoagulant treatment with and without aspirin. Thromb Haemost. 1995;74:506–10.

    PubMed  CAS  Google Scholar 

  39. Massel D, Little SH. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. J Am Coll Cardiol. 2001;37:569–78.

    Article  PubMed  CAS  Google Scholar 

  40. 2002 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2001.

  41. Brouwer MA, Verheugt FW. Oral anticoagulation for acute coronary syndromes. Circulation. 2002;105:1270–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robin J. Larson MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Larson, R.J., Fisher, E.S. Should aspirin be continued in patients started on warfarin?. J GEN INTERN MED 19, 879–886 (2004). https://doi.org/10.1111/j.1525-1497.2004.30419.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1111/j.1525-1497.2004.30419.x

Key words

Navigation